Catalyst
Slingshot members are tracking this event:
SELLAS Life Sciences (SLS) Provides FDA Type C Review Update for Nelipepimut-S (NPS) for Triple Negative Breast Cancer (TNBC); Phase 3 design and plan now finalized
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| SLS |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 14, 2020
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Triple Negative Breast Cancer, Nelipepimut-s
